The Latest in FDA Evaluations and Research

FDA News

Related Topics: FDA News, ERP Journal on Ulitzer

News Feed Item

See Acsis Pharmaceutical Solutions at LogiPharma and PDA/FDA Joint Regulatory Conference

Conference attendees get chance to discuss visibility, collaboration and brand protection challenges with the experts

MARLTON, N.J., Sept. 4, 2014 /PRNewswire/ -- Acsis Inc., the market leader for supply chain visibility, brand protection and serialization solutions, announced the company will be attending two major pharmaceutical industry conferences in September – PDA/FDA Joint Regulatory Conference, September 8-9 at the Renaissance Hotel, Washington DC, Booth # 58; and LogiPharma, September 16-18 in Princeton, NJ, Booth # 15.  Attendees will learn about Acsis' solutions, including Serialization Management, Partner Network Collaboration, Track & Trace, Visibility and Brand Protection. Industry experts will be available to address specific challenges.

Also at LogiPharma, John DiPalo, Chief Technology Officer for Acsis, will be giving a presentation, "Automating the Serialization of Clinical Trials," on September 16, 2014, TRACK A at 2:30 pm.  In this session, John will discuss how a major pharmaceutical client evolved from a manual process to fully integrated, real-time tracking of clinical trial products from the line up through the ERP system. Learn how this fully integrated solution improved the packaging process and streamlined the flow of product through the supply chain.

About Acsis Inc.
The Acsis suite is an innovative cloud-based software solution for brand protection, enterprise serialization and end-to-end supply chain visibility. Acsis enables global manufacturers to have actionable analytics and real-time visibility from people, processes, devices and systems across their supply network, with seamless ERP integration.

For more information, visit

SOURCE Acsis Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.